	US 12,358,909 B2
	Capsazepine analogs for the treatment of cancer and other proliferative diseases
Cara B. Gonzales, San Antonio, TX (US); and Stanton McHardy, Helotes, TX (US)
Assigned to BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Sep. 6, 2019, as Appl. No. 16/563,131.
Application 16/563,131 is a continuation of application No. 15/505,260, granted, now 10,457,676, previously published as PCT/US2015/046784, filed on Aug. 25, 2015.
Claims priority of provisional application 62/043,750, filed on Aug. 29, 2014.
Prior Publication US 2020/0024276 A1, Jan. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/155 (2006.01); A61K 31/165 (2006.01); A61K 31/17 (2006.01); A61K 31/4035 (2006.01); A61K 31/472 (2006.01); A61K 31/4745 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07C 211/29 (2006.01); C07C 233/29 (2006.01); C07C 275/24 (2006.01); C07C 335/12 (2006.01); C07D 209/44 (2006.01); C07D 213/68 (2006.01); C07D 217/06 (2006.01); C07D 223/16 (2006.01)

CPC C07D 471/04 (2013.01) [A61K 31/155 (2013.01); A61K 31/165 (2013.01); A61K 31/17 (2013.01); A61K 31/4035 (2013.01); A61K 31/472 (2013.01); A61K 31/4745 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07C 211/29 (2013.01); C07C 233/29 (2013.01); C07C 275/24 (2013.01); C07C 335/12 (2013.01); C07D 209/44 (2013.01); C07D 213/68 (2013.01); C07D 217/06 (2013.01); C07D 223/16 (2013.01)]

9 Claims

1. A method of treating oral squamous cell carcinoma, prostate cancer, colon cancer, pancreatic cancer, bladder cancer, cervical cancer, non-small cell lung cancer, breast cancer, glioma, glioblastoma or endometrial cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula

or a pharmaceutically acceptable salt, enantiomer or tautomer thereof.